CytoAgents

R&D

Bolstering CAR-T therapies by tackling CRS, with Teresa Whal...

In interview with Teresa Whalen, the CEO of CytoAgents, a clinical-stage drug development company working on a treatment for cytokine release syndrome

News

Readout for AZ's hypoparathyroidism drug raises questions

AstraZeneca may struggle to differentiate eneboparatide, a hypoparathyroidism drug from its $800m takeover of Amolyt, from Ascendis' rival Yorvipath.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/register.png

Digital

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Editor's Picks